Objective: To investigate the prevalence and risk factors of heart valve disease in patients having PD treated with pergolide.
Data Sources:
Using an end point of moderate to severe heart valve regurgitation, we performed a metaanalysis of patients having Parkinson disease (PD) treated with pergolide mesylate vs control subjects by searching PubMed (January 1, 1966, to April 1, 2007) and the Cochrane databases to identify English-language prospective observational studies that reported echocardiographic data.
Conclusion:
Heart valve disease is independently associated with the use of pergolide treatment in patients having PD and correlates with its cumulative dose. got-derived dopamine receptor agonist used to treat Parkinson disease (PD) and restless leg syndrome. Pergolide is known to induce pulmonary, pleural, and retroperitoneal fibrosis similar to that induced by other ergot derivatives. 1, 2 Following occasional anecdotal case reports, comparative studies [3] [4] [5] [6] [7] [8] reported heart valve disease (HVD) associated with pergolide intake. A recent large case-control study 7, 9 found an association between HVD and pergolide or cabergoline intake, but other studies 6, 10, 11 did not demonstrate this association. A causal relationship between pergolide use and a potential adverse effect remains to be established.
Although the first reported cases were symptomatic, most of the following studies found asymptomatic HVD in patients using pergolide. 12 The prevalence was rare based on cases registered in drug vigilance databases, whereas studies 3, 5, 13 that included systematic echocardiographic findings reported abnormal heart valves in up to 40% of patients having PD treated with pergolide. A dose association was found, 5, 7, 10 although there were some controversies about the relative importance of the daily and cumulative doses. On discovery of asymptomatic heart valve regurgitation in a pergolide-treated patient with PD, an accurate diagnosis may be difficult in clinical practice because of the association between age and heart valve regurgitation.
14 The prevalence and risk factors of this drug-induced adverse effect are of particular interest because moderate to severe valve regurgitation was recently associated with higher mortality in the general population. 15 We conducted a prevalence study and performed a meta-analysis of similar published studies to investigate the prevalence and potential risk factors of moderate to severe heart valve regurgitation associated with pergolide treatment in PD.
METHODS

STUDY DESIGN
Patients were recruited from April 1, 2005 , to August 31, 2006, in the Department of Neurology, Hô pital de la Pitié-Salpêtrière, Paris, France. Inclusion criteria were diagnosis of PD, age older than 18 years, Hoehn and Yahr 16 score of 1 to 4, treatment with pergolide for more than 3 months (pergolidetreated group), or no treatment with pergolide (control group). Patients with a history of HVD were excluded. Previous or current treatment with other dopaminergic agonists was allowed in both groups. Treatment history was retrospectively reviewed from patients' medical records and historical data. The cumulative dose of pergolide was calculated as the mean daily dose (cumulative dose per exposure duration). Data were available for all but 1 patient, who was subsequently excluded from the multiple regression analysis. Echocardiography was performed by a cardiologist ( J.-B.A.-K. or E.F.) blinded to treatment status. The primary end point was moderate to severe regurgitation in at least 1 heart valve. All patients provided written informed consent; the study was approved by the local ethics committee and was registered on the Web site for clinical trials.
ECHOCARDIOGRAPHY
Echocardiographic examinations were performed (Siemens Acuson Sequoia; Siemens Acuson, Mountain View, California), and data were saved using commercially available software (Image Arena Tomtec, Unterschleissheim, Germany). Valve thickness was measured in 2 dimensions (diastolic measurements for mitral and tricuspid valves and systolic measurements for the aortic valve). A valve was considered restrictive when thicker than normal and associated with retraction. Tenting area and tenting distance of the mitral valve were measured. 17 Severity of heart valve regurgitation was assessed using pulsed, continuous, and color Doppler imaging, according to the recommendations of the American Society of Echocardiography. 18 Briefly, for mitral regurgitation, the assessment was based on a combination of the following variables: jet area color flow, vena contracta width, proximal isovelocity jet area, and calculation of flow and stroke volume at the mitral annulus and the left ventricular outflow levels. For aortic regurgitation, the assessment was based on jet width in the left ventricular outflow tract, vena contracta width, jet pressure half time on continuous Doppler imaging, and diastolic flow reversal in the descending aorta. Finally, for tricuspid regurgitation, the assessment was based on jet area color flow, vena contracta width, and hepatic vein flow. When present, regurgitation was graded as mild, moderate, or severe. Pulmonary regurgitation evaluation was not performed systematically, and the results were considered. Systolic pulmonary pressure was measured as described previously.
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META-ANALYSIS
We conducted an electronic search of PubMed ( January 1, 1966, to April 1, 2007 ) and the Cochrane databases by means of the Quality of Reporting of Meta-analyses approach strategy 20 to identify all English-language publications using the keywords pergolide, valvular heart disease, valvulopathy, and fibrosis. Studies included in the meta-analysis were prospective studies having a control group and reporting data on heart valve regurgitation. Of 60 articles reviewed, we excluded 53 (21 reviews, 21 studies without echocardiography data, 8 case reports, 1 retrospective study, 1 case-control study, and 1 study without a pergolide study group). The end point was defined as moderate to severe regurgitation (ie, greater than minimal, trace, or trivial) in 1 heart valve or more. In 1 study, because the valvular scoring system was different, the end point for meta-analysis was defined as "important valvular disease (regurgitant jet Ն2/4) suggestive for restrictive valvular disease or restrictive tricuspid disease even if less than 2/4." 5(p1180) The mean values for age, pergolide cumulative dose, and exposure duration were collected. For 1 study, 8 2 patients (1 pergolide-treated patient and 1 control subject) 
STATISTICAL ANALYSIS
The t test was used to compare continuous variables; the 2 test or bilateral exact Fisher test for frequencies. Univariate and multivariate logistic regression analysis (logit) was performed using commercially available software (Statistica 7.1; Statsoft France, Maisons-Alfort, France) to analyze associations between the presence of moderate to severe regurgitation (dependent variable) and age, sex, duration of PD, body mass index, and bromocriptine mesylate and pergolide exposure (independent variables). For the meta-analysis, the pooled estimate of the overall odds ratio (OR) was calculated using the inverse variance weighted OR for each study (EasyMA 2001 software; Department of Clinical Pharmacology, Cardiological Hospital, Lyon, France). The inverse variance weighted linear regression model was used to test the relationship between risk difference and age, pergolide cumulative dose, and exposure duration.
RESULTS
PATIENT CHARACTERISTICS
One hundred forty-six patients were enrolled in the study. Thirteen patients (10 in the pergolide-treated group) did not undergo echocardiography because of noncompliance (n=10), withdrawal of consent (n=2), or technical problems (n = 1). Overall, 86 pergolidetreated patients and 47 control subjects underwent standardized echocardiography. The pergolide-treated patients had a mean ± SD cumulative dose of 2555 ± 1662 mg, daily dose of 1.8 ± 0.9 mg, and exposure duration of 48 ± 18 months ( Table 1) . Only 1 patient received a daily dose higher than 5 mg. Although there was no statistically significant difference for age, sex, body mass index, or cardiovascular risk factors, patients in the pergolide-treated group had a higher Hoehn and Yahr mean score and a longer mean duration of PD. These differences were expected because pergolide therapy is recommended only after the failure of other medications (ie, in patients with more severe disease). Bromocriptine use was similar in both groups. No patient received cabergoline; 5 patients treated with lisuride during 1 to 7 years had discontinued the drug more than 2 years before inclusion in the study. Nonergot dopamine agonists (pramipexole dihydrochloride or ropinirole hydrochloride) were prescribed to 28 control subjects (59.6%); these drugs had previously been taken by 22 patients (25.6%) in the pergolide-treated group. 
VALVE REGURGITATION PREVALENCE AND PERGOLIDE TREATMENT
Moderate to severe regurgitation in at least 1 heart valve was observed in 15 patients (17.4%) in the pergolidetreated group compared with 2 patients (4.3%) in the control group (P=.03) ( Table 2 ). The OR was 5.5 (95% confidence interval [CI], 1.2-26) after adjustment for age. Valve analysis demonstrated a statistically significant higher proportion of tricuspid moderate to severe regurgitation in the pergolide group. No patient had severe valve regurgitation. Moderate to severe regurgitation in multiple valves was found in 4 pergolide-treated patients and in no control subjects. Tenting area, tenting distance, and systolic pulmonary arterial pressure were not different between the groups (data not shown). However, patients with primary criteria in the pergolide-treated group, that is, pergolidetreated patients with moderate to severe regurgitation, had a higher mean±SD systolic pulmonary arterial pressure (39±9 vs 32±6 mm Hg) and more frequent restrictive or thickened valves (67% vs 17%) (PϽ.001 for both). No heart valve regurgitation due to valve prolapse, annular dilatation, or calcification was observed in patients with moderate to severe regurgitation. To investigate possible confounding factors, we performed a logistic regression analysis ( Table 3 ). In the univariate analysis, a positive and statistically significant association was only found for pergolide use. No association was found for any other drug, including bromocriptine, lisuride, or both (data not shown). There was a tendency for an association with age, as expected by previous findings in the general population. 15 After adjustment for age, sex, and PD duration, moderate to severe regurgitation was still statistically significantly associated with pergolide use.
PERGOLIDE DOSE EFFECT
Patients with moderate to severe regurgitation had higher mean±SD pergolide cumulative (34±14 vs 24±14 mg/ kg) and daily (49±30 vs 34±20 µg/kg) doses (P=.01 for both). Moderate to severe regurgitation was statistically sig- nificantly associated with cumulative and daily doses of pergolide (P = .02 for both) ( Table 4 ). In contrast, the mean±SD pergolide exposure duration was similar in patients with and without the primary end point (46±18 vs 48±18 months, P=.68) and was not associated with moderate to severe regurgitation. Higher cumulative doses were observed in patients with multiple valve regurgitation ( Figure 1A ). In addition, the presence of a thickened or restrictive valve was associated with the cumulative dose of pergolide (OR, 1.30; 95% CI, 1.04-1.63; P=.02). Systolic pulmonary arterial pressure was correlated with pergolide cumulative dose (r=0.29, P=.02) ( Figure 1B ). Tenting area and tenting distance were not correlated with pergolide cumulative dose (data not shown).
META-ANALYSIS
Seven studies and the present study met the selection criteria (see the "Meta-analysis" subsection of the "Methods" section) and were included in the meta-analysis (394 patients treated with pergolide and 280 control subjects) ( Table 5 ). All trials showed higher moderate to severe regurgitation prevalences in the pergolidetreated group, although only 2 were statistically significantly higher prevalences (Figure 2) . Altogether, 86 patients in the pergolide-treated group (21.8%) and 20 patients in the control group (7.1%) had moderate to severe regurgitation in at least 1 heart valve, resulting in an overall OR of 3.1 (95% CI, 1.7-5.7) (P Ͻ .001). The risk difference of moderate to severe valve regurgitation was statistically significantly correlated with pergolide cumulative dose (r=0.90, PϽ .001) (Figure 3 ). In contrast, no statistically significant correlation was found with age (r=0.11, P=.69) or with pergolide exposure duration (r =0.05, P =.85).
COMMENT
Our data support an association between pergolide treatment and HVD in patients with PD. However, the absence of echocardiographic data before treatment precluded demonstration of a direct cause-effect relationship. The overall estimated OR was 3.1 for moderate to severe regurgitation in the meta-analysis. Therefore, the lack of a statistically significant association in previous studies 6, 10, 11 may be because of the small samples used. In addition, we provide evidence for a cumulative dose relationship in this association. The lower prevalence and severity of HVD found in our population compared with those in other studies 3, 5 may be explained by the low doses Figure 2 . Meta-analysis of moderate to severe valve regurgitation (fixed model). CI indicates confidence interval; OR, overall odds ratio. 2 Test for association was performed on the estimated odds ratio. 
